Biography

Having joined 3i in 2000, Klaus is partner and head of 3i Germany's healthcare venture capital team. He has more than 12 years experience in the pharmaceutical industry as Senior Manager in Research and Business Development at Schering AG in Berlin and as Director of Business Development at ASTA Medica, a Degussa & Hüls group company in Frankfurt.Klaus specialises in healthcare investments including medtech across Europe. He was on 3i’s side responsible for the IPOs of Epigenomics, Jerini and Santhera as well as the acquisition of Evotec Neuroscience by Evotec. Investments he recently led have been Elbion in Germany and Zonare and Glucon in the US. He is member of the Boards of Elbion, Immatics, Amaxa, Glucon and observer at Zonare. He is a member of LES (Licensing European Society) and is also a fellow of the Kellogg School of Management at Northwestern University in Chicago. Klaus holds a PhD in Biology and Pharmacology from the University of Mainz, Germany as well as an MBA from WHU / Kellogg Northwestern University in Chicago.